Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | |||
---|---|---|---|---|---|---|
Aktuell sind keine Nachrichten verfügbar, die den gewählten Kriterien entsprechen. |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
NOVONESIS | 51,86 | +0,08 % | NASDAQ OMX Nordic: Change of name and ticker code for Novozymes (97/24) | The Extraordinary General Meeting (EGM) of Novozymes A/S (Novozymes) held on
March 4, 2024 approved a secondary name of the company Novonesis A/S. As a
consequence of the name change, Novozymes has... ► Artikel lesen | |
GENMAB | 256,30 | -0,16 % | GENMAB A/S - 6-K, Report of foreign issuer | ||
ARBUTUS BIOPHARMA | 2,546 | +0,24 % | Arbutus Biopharma Corporation: Arbutus Reports Fourth Quarter and Year End 2023 Financial Results and Provides Corporate Update | On-track to report key clinical data in 2024 from two on-going Phase 2a clinical trials with imdusiran and the Phase 1a/1b clinical trial with AB-101 Plans to initiate a third Phase 2a clinical trial... ► Artikel lesen | |
MOLECULIN BIOTECH | 4,080 | -2,16 % | JTC Team, LLC: Moleculin Biotech Participates in Virtual Investor "What This Means" Segment Hosted by JTC Team | Moleculin CEO, Walter Klemp highlights Annamycin differentiation in the current AML treatment landscape and potential opportunity FRENCHTOWN, NJ / ACCESSWIRE / April 25, 2024 / JTC Team ("JTC"), a fully... ► Artikel lesen | |
BIOXCEL THERAPEUTICS | 2,400 | -1,15 % | BioXcel Therapeutics Announces Late-Breaking Abstract on Preliminary Findings from Phase 2 Investigator-Sponsored Trial of BXCL701 and KEYTRUDA in Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) Selected for Presentation at 2024 ASCO Annual Meeting | Poster presentation scheduled for June 1, 2024, 1:30-4:30 PM CT /2:30-5:30 PM ET Trial being led by Georgetown University's Lombardi Comprehensive Cancer Center NEW HAVEN, Conn., April 24, 2024 (GLOBE... ► Artikel lesen | |
SENSEI BIOTHERAPEUTICS | 0,950 | -1,04 % | Sensei Biotherapeutics to Present Topline Clinical Data from the SNS-101 Phase I Dose Escalation Study at the 2024 ASCO Annual Meeting | ||
VERICEL | 43,400 | +2,36 % | Vericel Corporation: Vericel to Report First-Quarter 2024 Financial Results on May 8, 2024 | ||
MUSTGROW BIOLOGICS | 0,726 | +0,28 % | MustGrow Biologics Corp.: MustGrow Biologics to Present at the Planet MicroCap Showcase | MustGrow Biologics to Present at the Planet MicroCap Showcase: VEGAS 2024 on Wednesday, May 1, 2024 & 1x1 Meetings on Thursday, May 2, 2024Saskatoon, Saskatchewan--(Newsfile Corp. - April 17, 2024)... ► Artikel lesen | |
REGENXBIO | 14,900 | 0,00 % | REGENXBIO Inc.: Regenxbio Announces New Positive Initial Efficacy Data From Affinity Duchenne Trial | New three-month assessment in first patient at dose level 2 demonstrates robust microdystrophin expression
Patient aged 12 years at dosing had expression level at 75.7% of control
Early evidence... ► Artikel lesen | |
AKEBIA | 1,251 | +0,56 % | Akebia Therapeutics, Inc. - 8-K, Current Report | ||
FENNEC PHARMACEUTICALS | 8,450 | +2,42 % | FENC breaks ground on expansion of green PET production facility | ||
ZEVRA THERAPEUTICS | 4,200 | -0,47 % | Zevra Therapeutics Presents New Data on the Long-Term Safety and Efficacy of Arimoclomol as a Treatment for Niemann-Pick Disease Type C at the SIMD 45th Annual Meeting | The oral presentation highlighted data from Zevra's Expanded Access Program demonstrating a consistent safety profile CELEBRATION, Fla., April 15, 2024 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc.... ► Artikel lesen | |
REVANCE THERAPEUTICS | 3,080 | +0,65 % | OPI, RVNC and AQST are among after hour movers | ||
CORVUS PHARMACEUTICALS | 1,292 | -5,42 % | Corvus Pharmaceuticals, Inc.: Corvus Pharmaceuticals Announces Initiation of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis | Atopic dermatitis is the first immune disease indication being studied in the clinic for soquelitinib, the Company's selective ITK inhibitor Corvus anticipates releasing initial clinical data from... ► Artikel lesen | |
CARTESIAN THERAPEUTICS | 19,300 | 0,00 % | Cartesian Therapeutics, Inc. - 8-K, Current Report |